Swiss National Bank Kodiak Sciences Inc. Transaction History

Swiss National Bank

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$4.81 - $8.88 $29,340 - $54,168	-6,100 Reduced 7.67%	73,400 $455,000
Q2 2022 Aug 09, 2022	BUY	$5.04 - $9.48 $30,744 - $57,828	6,100 Added 8.31%	79,500 $607,000
Q1 2022 May 09, 2022	BUY	$7.09 - $89.45 $38,286 - $483,030	5,400 Added 7.94%	73,400 $567,000
Q3 2021 Nov 08, 2021	BUY	$81.97 - $106.94 $65,576 - $85,552	800 Added 1.19%	68,000 $6.53 Million
Q2 2021 Aug 06, 2021	SELL	$77.2 - $126.54 $548,120 - $898,434	-7,100 Reduced 9.56%	67,200 $6.25 Million
Q1 2021 May 07, 2021	BUY	$110.45 - $164.47 $55,225 - $82,235	500 Added 0.68%	74,300 $8.43 Million
Q4 2020 Feb 05, 2021	BUY	$60.78 - $154.03 $1.42 Million - $3.6 Million	23,400 Added 46.43%	73,800 $10.8 Million
Q3 2020 Nov 09, 2020	BUY	$45.05 - $59.27 $36,040 - $47,416	800 Added 1.61%	50,400 $2.98 Million
Q2 2020 Aug 05, 2020	SELL	$42.74 - $66.25 $21,370 - $33,125	-500 Reduced 1.0%	49,600 $2.68 Million
Q1 2020 May 08, 2020	BUY	$38.18 - $73.95 $30,544 - $59,160	800 Added 1.62%	50,100 $2.39 Million
Q4 2019 Feb 06, 2020	BUY	$13.9 - $76.65 $685,270 - $3.78 Million	49,300 New	49,300 $3.55 Million

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $417M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.